Showing 15 posts of 44 posts found.


Eylea sales jump helps boost Regeneron in Q2 results

August 5, 2016
Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results

Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …


Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations

August 2, 2016
Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results

Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …


Earnings drop at Sanofi as it looks for a quick Medivation resolution

July 29, 2016
Medical Communications, Research and Development 2016, Medivation, Q2, Sanofi, earnings

Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division …


Cholesterol drugs drag AstraZeneca’s profits down in latest financial results

July 28, 2016
Research and Development, Sales and Marketing 2016, AstraZeneca, Q2, h1, results

AstraZeneca has maintained its financial outlook for 2016, despite its Q2 and H1 results showing sharp falls in core earnings …

Pharma unit helps boost profits at Bayer

July 27, 2016
Research and Development, Sales and Marketing Bayer, Q2, results

The pharmaceutical division at Bayer was the driving force, as the company announced a 5.7% increase in second quarter profit …


Gilead lowers full-year guidance as sales and profits down in Q2

July 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing 2016, Gilead, Q2, results

Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …


Roche beats forecasts in strong H1 results

July 21, 2016
Research and Development, Sales and Marketing 2016, Q2, Roche, h1, results

Roche has published very encouraging full results for the first half of this year, with cancer drug sales helping to …


J&J boosted by pharma revenue in Q2 results

July 20, 2016
Research and Development 2016, Johnson and Johnson, Q2, results

Shares at Johnson and Johnson have reached a record high of over $125 after pharma revenues helped to raise full …


Novartis lowers core operating profit outlook in Q2 results

July 19, 2016
Manufacturing and Production, Research and Development, Sales and Marketing 2016, Novartis, Q2, results

Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …

Sanofi image

Sanofi sees FDA approval for diabetes drug

February 26, 2015
Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4

US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …

Pfizer New York HQ

Pfizer revenue drops, but new cancer drugs shine

July 29, 2014
Research and Development, Sales and Marketing Cancer, Inlyta. axitinib, Lipitor, Lyrica, Pfizer, Q2, Sutent, viagra

Pfizer saw a 2% drop in sales for the second quarter but has pointed to the stellar growth of its …

gsk image

Another major drop in sales for GSK

July 23, 2014
Sales and Marketing China, GSK, Q2, Witty, bribery, sales, scandal, sex

GlaxoSmithKline posted a 4% slide in revenue for the second quarter today as its recovery from a slew of patent …


New drugs see J&J sales rise

July 17, 2014
Medical Communications, Sales and Marketing J&J, JJ, Q2, hepatitis C, olysio, sovaldi

Johnson & Johnson saw sales rise 9.1% to $19.5 billion year on year on the back of a strong performance …

Erbitux image

Merck KGaA declines in Q2

August 7, 2013
Sales and Marketing Erbitux, Merck KGaA, Q2, Serono

Sales of cancer drug Erbitux dropped as Merck Serono’s revenues for the second quarter of 2013 dipped year-on-year, the firm …

Seroquel loss hits AstraZeneca

August 2, 2013
Sales and Marketing AstraZeneca, Q2, Seroquel, symbicourt

Loss of exclusivity on brands such as the antipsychotic Seroquel IR helped put a $500 million dent in AstraZeneca’s performance …

Latest content